Mark Epping-Jordan, Chief Scientific Officer, Resigns
March 26, 2008 18:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 26 March 2008 - Addex Pharmaceuticals (SWX:ADXN) announced today that Mark Epping-Jordan, chief scientific officer, has resigned for personal reasons and will leave the company in...
Disclosure of Shareholdings in accordance with Stock Market Rules
March 17, 2008 02:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 17 March 2008 - Addex Pharmaceuticals (SWX:ADXN) announced today that on March 13, 2008, The Swiss Helvetia Fund, Inc. 1270 Avenue of the Americas, Suite 400, New York,...
Addex Pharmaceuticals 2007 Financial Results
February 26, 2008 01:00 ET
|
Addex Therapeutics
Addex 2007 Financial Results (PDF) Addex 2007 résultats financiers (PDF)
Addex Finanzergebnis 2007 (PDF)
Geneva, Switzerland - Allosteric modulation company Addex Pharmaceuticals...
Addex Achieves First Milestone in Parkinson's Disease Collaboration with Merck & Co., Inc.
February 25, 2008 11:38 ET
|
Addex Therapeutics
Collaboration Targets a Non-Dopaminergic Approach to Treating Parkinson's Disease
Geneva, Switzerland - Allosteric modulation company Addex Pharmaceuticals (SWX:ADXN) announced...
Addex Full Year 2007 Financial Results Next Tuesday
February 21, 2008 12:27 ET
|
Addex Therapeutics
Conference call & webcast at 10:00 CET on 26 February 2008
Geneva, Switzerland, 21 February 2008- Addex Pharmaceuticals Ltd. (SWX:ADXN) will discuss its full year 2007 financial results during...
Addex and Merck & Co., Inc. Enter License Agreement to Develop a Drug Candidate for Schizophrenia
January 03, 2008 01:00 ET
|
Addex Therapeutics
Second Merck Deal Demonstrates the Value of Addex' Allosteric Modulator Platform
Addex to Host Webcast and Conference Call Today at 5:00 pm CET (11:00 am EST)English Version PDF French...
Addex Announces ADX10059 Phase IIa Acute Anxiety Data
January 03, 2008 01:00 ET
|
Addex Therapeutics
Teleconference & Webcast Today at 17:00 CET (11 am EDT)
English Version PDFFrench Version PDF German Version PDF
Geneva, Switzerland - Allosteric modulation company...
Zusammenarbeit von Addex und Merck & Co. zur Entwicklung von Medikamenten bei Parkinson
December 03, 2007 01:30 ET
|
Addex Therapeutics
Das Ziel der Zusammenarbeit ist eine nicht-dopaminerge Herangehensweise bei der Behandlung
der Parkinsonkrankheit
Addex veranstaltet heute um 17:00 Uhr MEZ (11:00 Uhr EDT) einen Webcast...
Addex and Merck & Co., Inc. Collaborate to Develop Drugs for Parkinson's Disease
December 03, 2007 01:30 ET
|
Addex Therapeutics
Collaboration Targets a Non-Dopaminergic Approach to Treating Parkinson's Disease
Addex to Host Webcast and Conference Call Today at 5:00 pm CET (11:00 am EST)
Geneva, Switzerland -...
Addex and Merck & Co., Inc. Collaborate to Develop Drugs for Parkinson's Disease
December 03, 2007 01:00 ET
|
Addex Therapeutics
PRESS...